Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07064122 · ClinicalTrials.gov registry record · Phase 1
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
A Phase 1 study of Haematologic Neoplasms, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT07064122 is a Phase 1 study of Haematologic Neoplasms that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 72 participants. The trial reports 20 study locations across 3 states.
The verdict
NCT07064122, a Phase 1 study of Haematologic Neoplasms, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in combination with other agents in participants with haematologic neoplasms.
Conditions Studied
Interventions
- DRUG AZD2962
Study Locations (20)
Other
- Research Site - Heidelberg
- Research Site - Melbourne
- Research Site - Shinagawa-ku
- Research Site - Yoshida-gun
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Barcelona
- Research Site - Madrid
- Research Site - Madrid
- Research Site - Pamplona
- Research Site - Salamanca
- Research Site - Valencia
- Research Site - Kaohsiung City
- Research Site - Tainan
- Research Site - Taipei
- Research Site - London
- Research Site - London
Florida
- Research Site - Miami
- Research Site - Tampa
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2028-10-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07064122
The ClinicalTrials.gov registry entry for NCT07064122 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Haematologic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which AZD2962 is the first listed.
NCT07064122 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07064122 about?
NCT07064122 is a clinical study titled "A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)". The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in combination with other agents in participants with haematologic neoplasm...
What is the current status of trial NCT07064122?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2025-11-03. Estimated completion is 2028-10-20.
What conditions does trial NCT07064122 study?
This clinical trial studies the following conditions: Haematologic Neoplasms.
What interventions are being tested in trial NCT07064122?
The interventions under investigation include: AZD2962 (DRUG).
Who is sponsoring clinical trial NCT07064122?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07064122 being conducted?
This trial has 20 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.